Anemia in Chronic Kidney Disease Market

The anemia in chronic kidney disease market has been comprehensively analyzed in IMARC's new report titled "Anemia in Chronic Kidney Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anemia in chronic kidney disease (CKD) is a prevalent complication characterized by a deficiency in red blood cells or hemoglobin. Hemoglobin plays a crucial role in transporting oxygen throughout the body, and its reduced levels in CKD patients can lead to fatigue, weakness, and shortness of breath. As the kidneys function to produce erythropoietin, a hormone essential for red blood cell production, their impairment in CKD contributes to anemia. Symptoms may also include pale skin, dizziness, and cold hands and feet. Diagnosing anemia in CKD involves blood tests to assess hemoglobin and other related parameters such as hematocrit and mean corpuscular volume. Additionally, healthcare providers may evaluate serum ferritin and transferrin saturation to determine iron status, a key factor in addressing anemia. Timely identification and management of anemia in CKD are crucial to enhance patients' quality of life and mitigate the risk of cardiovascular complications associated with inadequate oxygen delivery to tissues.

The escalating incidence of impaired kidney function that can affect the absorption and regulation of iron, leading to reduced iron availability for the production of hemoglobin, is primarily driving the anemia in the chronic kidney disease market. In addition to this, the inflating utilization of effective medications such as beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogs, which play a crucial role in managing the condition and thwarting further damage, is creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies that help in strengthening muscles, improving coordination, and enhancing gross motor skills, is also bolstering the market growth. Apart from this, the rising usage of pulsed dye laser procedures, targeting abnormal blood vessels to selectively destroy and lighten affected skin areas, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, a novel approach involving the introduction of functional genetic material into cells to replace or correct mutated or malfunctioning genes responsible for the disease, is expected to drive the anemia in the chronic kidney disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the anemia in chronic kidney disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for anemia in chronic kidney disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anemia in chronic kidney disease market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the anemia in chronic kidney disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the anemia in chronic kidney disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current anemia in chronic kidney disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the anemia in chronic kidney disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the anemia in chronic kidney disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the anemia in chronic kidney disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of anemia in chronic kidney disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of anemia in chronic kidney disease by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of anemia in chronic kidney disease by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with anemia in chronic kidney disease across the seven major markets?
• What is the size of the anemia in chronic kidney disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of anemia in chronic kidney disease?
• What will be the growth rate of patients across the seven major markets?

Anemia In Chronic Kidney Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for anemia in chronic kidney disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the anemia in chronic kidney disease market?
• What are the key regulatory events related to the anemia in chronic kidney disease market?
• What is the structure of clinical trial landscape by status related to the anemia in chronic kidney disease market?
• What is the structure of clinical trial landscape by phase related to the anemia in chronic kidney disease market?
• What is the structure of clinical trial landscape by route of administration related to the anemia in chronic kidney disease market?